Category: news

NEWTON, Mass.–(BUSINESS WIRE)–Cheetah Medical, a Massachusetts-based leader in non-invasive fluid
management, today announced it has concluded enrollment for the Fluid
Responsiveness Evaluation in Sepsis-associated Hypotension (FRESH) t…

DUBLIN–(BUSINESS WIRE)–The “Microcarrier
Market: Global Industry Analysis, Trends, Market Size, and Forecasts up
to 2024” report has been added to ResearchAndMarkets.com’s
offering.

The report predicts the global …

DUBLIN–(BUSINESS WIRE)–The “Strategic
Development of Neural Stem and Progenitor Cell Products” report
has been added to ResearchAndMarkets.com’s offering.

While the number of adult stem cell therapies entering clinical t…

Iktos’ generative modelling AI technology enables rapid and
cost-effective design of novel drugs

Collaboration agreement enables Merck KGaA, Darmstadt, Germany
access to Iktos AI technology across…

Recognition honors a CEO who has demonstrated visionary leadership
and active participation to advance the life sciences and biotech
industry

MALVERN, Pa.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/antibio…

LAVAL, Quebec–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Altasciences?src=hash" target="_blank"gt;#Altascienceslt;/agt;–Altasciences,
a mid-size CRO specializing in a flexible, innovative approach to
pro…

DEERFIELD, Ill.–(BUSINESS WIRE)–Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today named Heather Dixon
as its new senior vice president, global controller and chief accounting
officer, effective March 18, 2019.

Dixon wil…

ANN ARBOR, Mich.–(BUSINESS WIRE)–Millendo
Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage
biopharmaceutical company developing novel treatments for orphan
endocrine diseases, announced today that its clinical candidates,
…

— Edasalonexent Phase 3 PolarisDMD Trial Globally Enrolling Boys
with Duchenne Muscular Dystrophy —

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutica…

– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial
Progressing –

– Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase
2 Trial Completion Expected H2 2019 –

– Oral Plasma …